



---

Year: 2020

---

## **Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry**

Ghofrani, Hossein-Ardeschir ; Gomez Sanchez, Miguel-Angel ; Humbert, Marc ; et al ; Schwarz, Esther I ; Speich, Rudolf

**Abstract:** Objective The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. Methods EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms. Results In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase-Stimulator Trial [CHEST-2]). Conclusion Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified.

DOI: <https://doi.org/10.1016/j.rmed.2020.106220>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-194655>

Journal Article

Accepted Version

Originally published at:

Ghofrani, Hossein-Ardeschir; Gomez Sanchez, Miguel-Angel; Humbert, Marc; et al; Schwarz, Esther I; Speich, Rudolf (2020). Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*:106220.

DOI: <https://doi.org/10.1016/j.rmed.2020.106220>

Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension:  
Final safety data from the EXPERT registry

Hosseini-Ardeschir Ghofrani, Miguel-Angel Gomez Sanchez, Marc Humbert, David Pittrow, Gérald Simonneau, Henning Gall, Ekkehard Grünig, Hans Klose, Michael Halank, David Langleben, Repke J. Snijder, Pilar Escribano-Subias, Lisa M. Mielniczuk, Tobias J. Lange, Jean-Luc Vachiéry, Hubert Wirtz, Douglas S. Helmersen, Iraklis Tsangaris, Joan A. Barberá, Joanna Pepke-Zaba, Anco Boonstra, Stephan Rosenkranz, Silvia Ulrich, Regina Steringer-Mascherbauer, Marion Delcroix, Pavel Jansa, Iveta Šimková, George Giannakoulas, Jens Klotzsche, Evgenia Williams, Christian Meier, Marius M. Hoeper



PII: S0954-6111(20)30360-7

DOI: <https://doi.org/10.1016/j.rmed.2020.106220>

Reference: YRMED 106220

To appear in: *Respiratory Medicine*

Received Date: 17 May 2020

Revised Date: 5 November 2020

Accepted Date: 6 November 2020

Please cite this article as: Ghofrani H-A, Gomez Sanchez M-A, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano-Subias P, Mielniczuk LM, Lange TJ, Vachiéry J-L, Wirtz H, Helmersen DS, Tsangaris I, Barberá JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, Šimková I, Giannakoulas G, Klotzsche J, Williams E, Meier C, Hoeper MM, Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry, *Respiratory Medicine* (2020), doi: <https://doi.org/10.1016/j.rmed.2020.106220>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that,

during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.

## EXPERT primary manuscripts: credit author statement

Marius M. Hoeper. Conceptualization; methodology; investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Miguel-Angel Gomez Sanchez. Conceptualization; methodology; investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Marc Humbert. Conceptualization; methodology; investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

David Pittrow. Conceptualization; methodology; investigation; resources; writing – review & editing; supervision; project administration; approval of final draft for submission.

Gérald Simonneau. Conceptualization; methodology; investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Hossein-Ardeschir Ghofrani. Conceptualization; methodology; investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Henning Gall. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Ekkehard Grünig. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Hans Klose. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Michael Halank. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

David Langleben. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Repke J. Snijder. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Pilar Escribano-Subias. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Lisa M. Mielniczuk. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Tobias J. Lange. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Jean-Luc Vachiéry. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Hubert Wirtz. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Douglas S. Helmersen. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Iraklis Tsangaris. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Joan A. Barberá. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Joanna Pepke-Zaba. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Anco Boonstra. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Stephan Rosenkranz. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Silvia Ulrich. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Regina Steringer-Mascherbauer. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Marion Delcroix. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Pavel Jansa. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Iveta Šimková. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

George Giannakoulas. Investigation; resources; writing – review & editing; supervision; approval of final draft for submission.

Jens Klotsche. Conceptualization; methodology; software; validation; formal analysis; resources; data curation; writing – review & editing; visualization; approval of final draft for submission.

Evgenia Williams. Validation; formal analysis; data curation; writing – review & editing; approval of final draft for submission.

Christian Meier. Conceptualization; methodology; validation; writing – review & editing; supervision; project administration; funding acquisition; approval of final draft for submission.

Collaborators. Investigation; resources; supervision.

## Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

Hosseini-Ardeschir Ghofrani<sup>a,\*</sup>, Miguel-Angel Gomez Sanchez<sup>b</sup>, Marc Humbert<sup>c</sup>, David Pittrow<sup>d</sup>, Gérald Simonneau<sup>e</sup>, Henning Gall<sup>a</sup>, Ekkehard Grünig<sup>f</sup>, Hans Klose<sup>g</sup>, Michael Halank<sup>h</sup>, David Langleben<sup>i</sup>, Repke J. Snijder<sup>j</sup>, Pilar Escribano-Subias<sup>k</sup>, Lisa M. Mielniczuk<sup>l</sup>, Tobias J. Lange<sup>m</sup>, Jean-Luc Vachiéry<sup>n</sup>, Hubert Wirtz<sup>o</sup>, Douglas S. Helmersen<sup>p</sup>, Iraklis Tsangaris<sup>q</sup>, Joan A. Barberá<sup>r</sup>, Joanna Pepke-Zaba<sup>s</sup>, Anco Boonstra<sup>t</sup>, Stephan Rosenkranz<sup>u</sup>, Silvia Ulrich<sup>v</sup>, Regina Steringer-Mascherbauer<sup>w</sup>, Marion Delcroix<sup>x</sup>, Pavel Jansa<sup>y</sup>, Iveta Šimková<sup>z</sup>, George Giannakoulas<sup>aa</sup>, Jens Klotsche<sup>bb</sup>, Evgenia Williams<sup>cc</sup>, Christian Meier<sup>cc</sup>, Marius M. Hoeper<sup>dd</sup>.

<sup>a</sup>University of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany; member of the German Center for Lung Research (DZL)

<sup>b</sup>Respiratory Department, Ramón y Cajal University Hospital (IRYCIS), Madrid, Spain; Biomedical Research Networking Centre on Respiratory Diseases (CIBERES)

<sup>c</sup>Université Paris-Saclay, Inserm U999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France

<sup>d</sup>Institute for Clinical Pharmacology, Technical University, Dresden, Germany

<sup>e</sup>Université Paris-Sud, Le Kremlin-Bicêtre, Service de Pneumologie, Centre de Référence de l'Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre, Paris, France

<sup>f</sup>Centre for Pulmonary Hypertension, Thoraxclinic at Heidelberg University Hospital, Heidelberg, Germany

<sup>g</sup>Department of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

<sup>h</sup>Medical Clinic I, Department of Pneumology, University Hospital Carl Gustav Carus, Dresden, Germany

<sup>i</sup>Center for Pulmonary Vascular Disease, Jewish General Hospital, McGill University, Montreal, Quebec, Canada

<sup>j</sup>Department of Pulmonology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands

<sup>k</sup>Department of Cardiology, Hospital 12 de Octubre, Madrid, Spain; CIBER-CV (CIBER of cardiovascular disease)

<sup>l</sup>Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

<sup>m</sup>Department of Internal Medicine II, Division of Pneumology, University Medical Center, Regensburg, Germany

<sup>n</sup>Département de Cardiologie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium

<sup>o</sup>Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany

<sup>p</sup>Alberta Health Services, University of Calgary, Calgary, Alberta, Canada

<sup>q</sup>Second Department of Critical Care, University Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece

<sup>r</sup>Hospital Clínic-IDIBAPS, University of Barcelona, Barcelona; and Biomedical Research Networking Center on Respiratory Diseases (CIBERES), Madrid; Spain

<sup>s</sup>Pulmonary Vascular Disease Unit, Royal Papworth Hospital, Cambridge, UK

<sup>t</sup>VU Medisch Centrum, Amsterdam, The Netherlands

<sup>u</sup>Department III of Internal Medicine and Cologne Cardiovascular Research Center (CCRC), Cologne University Heart Center, Cologne, Germany

<sup>v</sup>Clinic of Pulmonology, University Hospital Zurich, Zurich, Switzerland

<sup>w</sup>Servicestelle für klinische Studien, Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria

<sup>x</sup>Department of Respiratory Diseases, University Hospitals of Leuven, and Respiratory Division, Department CHROMETA, KU Leuven – University of Leuven, Leuven, Belgium

<sup>y2nd</sup> Department of Medicine – Department of Cardiovascular Medicine, Charles University in Prague, Prague, Czech Republic

<sup>z</sup>Department of Cardiology and Angiology, Faculty of Medicine, Slovak Medical University & National Institute of Cardiovascular Diseases, Bratislava, Slovak Republic

<sup>aa</sup>Department of Cardiology I, Aristotle University of Thessaloniki, Thessaloniki, Greece

<sup>bb</sup>German Rheumatism Research Center Berlin, Leibniz Institute, Berlin, Germany

<sup>cc</sup>Bayer AG, Global Development, Global Medical Affairs, Berlin, Germany

<sup>dd</sup>Department of Respiratory Medicine and the German Center for Lung Research, Hannover Medical School, Hannover, Germany.

\*Corresponding author. University of Giessen and Marburg Lung Center (UGMLC), Giessen 35392, Germany; member of the German Center for Lung Research (DZL)

*E-mail address:* [Ardeschir.Ghofrani@innere.med.uni-giessen.de](mailto:Ardeschir.Ghofrani@innere.med.uni-giessen.de)

Tel: +49 641 994 2422

*Keywords:* Chronic thromboembolic pulmonary hypertension; riociguat; registry; real-world; clinical practice; safety



## ABSTRACT

*Objective:* The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice.

*Methods:* EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits and collated via case report forms.

*Results:* In total, 956 patients with CTEPH were included in the analysis. The most common AEs in these patients were peripheral edema/edema (11.7%), dizziness (7.5%), right ventricular (RV)/cardiac failure (7.7%), and pneumonia (5.0%). The most common SAEs were RV/cardiac failure (7.4%), pneumonia (4.1%), dyspnea (3.6%), and syncope (2.5%). Exposure-adjusted rates of hemoptysis/pulmonary hemorrhage and hypotension were low and comparable to those in the long-term extension study of riociguat (Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial [CHEST-2]).

*Conclusion:* Data from EXPERT show that in patients with CTEPH, the safety of riociguat in routine practice was consistent with the known safety profile of the drug, and no new safety concerns were identified.

## 1. Introduction

Chronic thromboembolic pulmonary hypertension (CTEPH) is a potentially fatal condition characterized by obstruction of the pulmonary vasculature by residual organized thrombi resulting in increased pulmonary vascular resistance (PVR), progressive vascular remodeling and pulmonary hypertension (PH), and subsequently right ventricular (RV) failure [1–4].

The treatment of choice in CTEPH is pulmonary endarterectomy (PEA), which potentially normalizes hemodynamics [5–7]. Up to 40% of patients are inoperable, however, and up to 51% exhibit persistent or recurrent CTEPH after PEA [5–13].

Riociguat is a first-in-class soluble guanylate cyclase stimulator recommended in European Respiratory Society/European Society of Cardiology guidelines for the treatment of patients with inoperable CTEPH or persistent/recurrent CTEPH after surgery [1]. Its efficacy and tolerability have been demonstrated in clinical trials [14, 15]. Agents that have been approved for pulmonary arterial hypertension (PAH) include prostacyclin analogs, endothelin receptor antagonists (ERAs), and phosphodiesterase type 5 inhibitors (PDE5i). With the exception of treprostinil in selected patients, these are not licensed for use in the treatment of patients with CTEPH, but can be administered off-label. Balloon pulmonary angioplasty (BPA) is a potentially effective option for selected inoperable patients [1, 16].

EXPosurE Registry RiociguaT in patients with PH (EXPERT) was a prospective, non-interventional registry to monitor the long-term safety of riociguat in clinical practice.

## Methods

### *2.1. Study design*

EXPERT (NCT02092818) was an international, multicenter, prospective, uncontrolled, non-interventional cohort study in patients treated with riociguat in 28 countries. The design is described in detail elsewhere (Hoeper et al., submitted). EXPERT was linked with the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA [<https://compera.org/>]), one of the largest global academic PH registries. This was consistent with guidance from regulatory authorities to use existing registries. EXPERT was conducted in accordance with good pharmacovigilance practices and was not requested, but was accepted, by the European Medicines Agency for the collection of additional long-term post-approval data on riociguat.

Patients were followed for 1 to 4 years from enrollment (including post-treatment safety follow-up) during a recruitment period of 3 years or until 30 days after stopping riociguat treatment. Data—including patient demographics, disease characteristics, riociguat dosing, hemodynamic parameters, changes in treatment, biomarkers, laboratory variables, adverse events (AEs) and serious adverse events (SAEs)—were collected at baseline and during routine clinical follow-up visits approximately every 3 to 6 months. Data were collected using a case report form (CRF) based on the COMPERA CRF, extended to obtain riociguat safety data.

### *2.2. Patients*

Patients who started treatment or were already being treated with riociguat were eligible for inclusion. Patients with disease duration  $\geq 6$  months were defined as prevalent, and those diagnosed within  $< 6$  months of enrollment were defined as incident. Patients were defined as riociguat-pretreated if they had been receiving riociguat for  $\geq 3$  months before registry entry and as riociguat-newly treated if they had been receiving riociguat for  $< 3$

months before entry. Riociguat-newly treated patients were therefore not necessarily incident patients and could have received PAH-approved therapy before riociguat. Newly treated patients were further categorized as switched or non-switched. Switched patients were newly treated patients who had stopped prior therapy  $\leq 10$  days before commencing riociguat.

### *2.3. Safety assessments*

The primary safety outcomes were AEs and SAEs, coded using Medical Dictionary for Regulatory Activities (MedDRA) preferred terms and System Organ Classes version 21.0. Secondary safety outcomes included AEs and SAEs of special interest (hypotension and hemoptysis/pulmonary hemorrhage). This report focuses on AEs and SAEs occurring during the treatment phase (onset date  $\leq 2$  days after the most recent dose of riociguat). An AE was considered serious if it: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization (with specific exceptions, defined in the protocol), resulted in persistent or significant disability or incapacity, was a congenital abnormality or birth defect, or was medically important. AEs and SAEs were classified as drug-related by according to the investigator's judgment. Deaths were analyzed in terms of all SAEs with a fatal outcome with onset during the treatment phase and the post-treatment phase (onset date  $> 2$  days after discontinuation until the end of 30-day safety follow-up).

### *2.4. Statistical methods and populations analyzed*


EXPERT was an observational study. All variables and outcomes, including comparisons between predefined groups (such as newly treated versus pretreated patients and prevalent versus incident patients) were analyzed descriptively. Statistical analyses of these comparisons were not performed because they would be of limited value without adjustment for differences between the groups. All analyses were performed with SAS 9.3. Categorical variables were analyzed using frequency tables and continuous variables by summary

statistics (mean  $\pm$  standard deviation [SD], median, and minimum–maximum range). The evaluable population consisted of all enrolled patients who did not withdraw consent and had received at least one dose of riociguat with dosing data available. Summary statistics and changes from baseline were calculated for 6-minute walking distance (6MWD), World Health Organization Functional Class (WHO FC), Borg Dyspnea Index, EuroQoL 5-dimensional Visual Analog Score (EQ-5D VAS), hemodynamic parameters, and biomarkers. This paper describes the results in patients with CTEPH. Results in patients with PAH are described separately (Hoeper et al., submitted).

## Results

### 3.1. Patient disposition

The evaluable population with CTEPH consisted of 956 patients of whom 537 (56.2%) were riociguat-pretreated and 419 (43.8%) were riociguat-newly treated. Approximately 86% of patients overall completed the study (Figure 1).



**Fig. 1.** Patient disposition.

CTEPH, chronic thromboembolic pulmonary hypertension. The numbers and percentages refer to the total CTEPH population enrolled (n = 969).

Chart shows primary reason for not completing per protocol.

<sup>a</sup>Other reasons for discontinuation are shown in supplementary Table 1.

**3.2. Demographics and baseline characteristics**

The mean age of the patients was  $66.3 \pm 13.7$  years; 570 patients (59.6%) were women. CTEPH was prevalent in 713 patients (74.6%), incident in 197 (20.6%), and unknown in 46 (4.8%). At baseline, riociguat was administered in combination with other PH-approved therapy in 198 patients (20.7%): with ERAs in 170 (17.8% [bosentan, 7.0%; macitentan, 7.0%; and ambrisentan, 3.8%]), prostanoids in 9 (0.9% [iloprost, 0.6%; intravenous treprostinil, 0.2%; and intravenous epoprostenol, 0.1%]), and both an ERA and prostanoid in 19 (2.0%). No patient received concomitant PDE5i. At Visit 6 (month 33–<39), 27.9% of patients were receiving combination therapy. In total, 901 patients (94.2%) had at least one comorbidity. Other baseline demographics are shown in Table 1. The operability status of the patients is shown in Figure 2.

**Table 1**

Baseline demographics and disease characteristics in the total CTEPH population (n = 956).

Characteristic	Mean $\pm$ SD or n (%)
Age, years	$66.3 \pm 13.7$
<b>Age group, years</b>	
< 65	366 (38.3)
65 to < 75	260 (27.2)
$\geq 75$	330 (34.5)
BMI, kg/m <sup>2</sup>	$28.6 \pm 15.2$
<b>BMI category, kg/m<sup>2</sup></b>	
< 18.5	24 (2.5)
18.5 to < 25	290 (30.3)
25 to < 30	348 (36.4)
$\geq 30$	294 (30.8)

**Smoking status**

Never	602 (63.0)
Former	314 (32.8)
Current	40 (4.2)
Age at initial PH diagnosis, years	62.7 ± 14.5
Median (IQR) disease duration, years	2.1 (0.7–4.9)
WHO FC, % (I/II/III/IV/unknown)	4.0/38.2/50.1/3.0/4.7
BNP, pg/mL (median, range)	131 (5–5844) (n = 148)
NT-proBNP, pg/mL (median, range)	602 (16–177 759) (n = 540)
6MWD, m	365 ± 128
<b>6MWD</b>	
< 320 m <sup>a</sup>	290 (30.3)
≥ 320 m	521 (54.5)
< 380 m	421 (44.0)
≥ 380 m <sup>a</sup>	390 (40.8)
Missing	145 (15.2)
EQ-5D VAS	62.3 ± 20.6 (n = 229)
Borg Dyspnea Index	3.8 ± 2.2 (n = 701)
mPAP, mmHg	43.0 ± 11.5 (n = 850)
PVR, dyn·s·cm <sup>-5</sup>	652 ± 502 (n = 767)
PAWP, mmHg	11.1 ± 5.0 (n = 809)
Cardiac index, L/min/m <sup>2</sup>	2.8 ± 4.4 (n = 756)
RAP, mmHg	9.0 ± 5.6 (n = 710)
SvO <sub>2</sub> (%)	63.7 ± 9.2 (n = 613)
<b>Riociguat daily dose at initial study visit, mg</b>	
Mean	6.9 ± 1.4 (n = 934)
Median (range)	7.5 (1.5–7.5) (n = 934)
<b>Riociguat median daily dose at initial study visit (mg)</b>	
≤ 2.5	13 (1.4)
> 2.5 to 4.5	108 (11.3)
> 4.5 to 6	90 (9.4)
> 6 to 7.5	723 (75.6)
Missing	22 (2.3)
Concomitant CCB	22 (2.3)
<b>Concomitant anticoagulation therapy</b>	
Oral anticoagulation	861 (90.1)
Vitamin K antagonist	506 (52.9)
Direct oral anticoagulant	190 (19.9)
Other oral anticoagulation <sup>b</sup>	159 (16.6)
Other anticoagulant <sup>b</sup>	66 (6.9)

Concomitant antiplatelet agents	44 (4.6)
---------------------------------	----------

**Comorbidity**

At least one medical history finding	901 (94.2)
Arterial hypertension	445 (46.5)
Venous thromboembolism	431 (45.1)
Thyroid disease	183 (19.1)
Diabetes mellitus	123 (12.9)
Cancer	123 (12.9)
Coronary heart disease	122 (12.8)
Obstructive sleep apnea	99 (10.4)
History of hemoptysis/lung bleeding	37 (3.9)
Other	759 (79.4)

---

6MWD, 6-minute walking distance; BMI, body mass index; BNP, brain natriuretic peptide;

CCB, calcium channel blocker; CTEPH, chronic thromboembolic pulmonary hypertension;

EQ-5D VAS, EuroQoL 5-dimensional Visual Analog Score; IQR, interquartile range; mPAP,

mean pulmonary artery pressure; NT-proBNP, N-terminal prohormone of brain natriuretic

peptide; PAWP, pulmonary artery wedge pressure; PEA, pulmonary endarterectomy; PH,

pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure;

SD, standard deviation; SvO<sub>2</sub>, saturated venous oxygen; WHO FC, World Health

Organization functional class.


Data are mean  $\pm$  SD or number (%) unless otherwise stated.

Results are for all patients (n = 956) unless otherwise stated.

<sup>a</sup>Thresholds chosen (380 m prespecified) based on available (6MWD) cohort data at the time indicating good or poor prognosis in PAH.

<sup>b</sup>As indicated by the investigator on the CRF.





**Fig. 2.** Operability status.

BPA, balloon pulmonary angioplasty; CTEPH, chronic thromboembolic pulmonary hypertension; PEA, pulmonary endarterectomy.

Persistent CTEPH after PEA or BPA were determined by the investigator.

### 3.3. Riociguat safety

#### 3.3.1. Total CTEPH population

In the total population with CTEPH, the median (range) duration of observation and riociguat treatment was 504.0 (0.0–1367.0) days and 493.5 (0.0–1367.0) days, respectively. In total, 615 patients (64.3%) experienced AEs and 365 (38.2%) experienced SAEs. These events were considered drug-related by the investigator in 148 (15.5%) and 34 (3.6%) patients, respectively. The most common AEs and SAEs are shown in Table 2. Discontinuation due to AEs and SAEs occurred in 55 patients (5.8%) and 38 patients (4.0%), respectively. The most common AEs or SAEs leading to discontinuation are shown in supplementary Table 2. Safety data for patients according to use of riociguat as monotherapy or in combination with other PAH-approved drugs are shown in supplementary Table 3. Rates of AEs and SAEs (68.2–88.9% and 44.1–66.7%, respectively) were

numerically higher with prostanoid-containing regimens (78.9–88.9% and 57.9–66.7%, respectively) than with riociguat monotherapy or riociguat + ERA (62.8–68.2% and 36.0–44.1%, respectively), but the numbers of patients receiving prostanoids were small.

**Table 2**

Most common AEs and SAEs in the total CTEPH population (n = 956).

AEs <sup>a</sup>	n (%)
Peripheral edema/edema	112 (11.7) <sup>b</sup>
Dyspnea	81 (8.5)
RV failure/cardiac failure	74 (7.7) <sup>c</sup>
Dizziness	72 (7.5)
Pneumonia	48 (5.0)
SAEs <sup>d</sup>	
RV failure/cardiac failure	71 (7.4) <sup>e</sup>
Pneumonia	39 (4.1)
Dyspnea	34 (3.6)
Syncope	24 (2.5)
PH <sup>e</sup>	22 (2.3)

AE, adverse event; CTEPH, chronic thromboembolic pulmonary hypertension; PH, pulmonary hypertension; RV, right ventricular; SAE, serious adverse event.

<sup>a</sup>Preferred-term AEs reported in  $\geq 5\%$  of patients.

<sup>b</sup>Including peripheral edema in 73 patients (7.6%) and edema in 42 patients (4.4%).

<sup>c</sup>Including RV failure in 61 patients (6.4%) and cardiac failure in 16 patients (1.7%).

<sup>d</sup>Preferred-term SAEs reported in  $\geq 2\%$  of patients.

<sup>e</sup>Including RV failure in 59 patients (6.2%) and cardiac failure in 15 patients (1.6%).

<sup>e</sup>Preferred term for worsening of the condition.

Note. Patients with peripheral edema/edema, or RV failure/cardiac failure could have both events.

Hemorrhages were reported in 110 patients (11.5%) and serious hemorrhages in 57 patients (6.0%). These events were considered by the investigator to be related to riociguat in nine (0.9%) and four patients (0.4%), respectively. Three patients (0.3%) discontinued riociguat as a result of a hemorrhage. The most frequently occurring hemorrhages were


epistaxis in 30 patients (3.1%) and hemoptysis in 26 patients (2.7%). The most common serious hemorrhages were hemoptysis in 16 patients (1.7%) and gastrointestinal hemorrhage in five patients (0.5%). Of all patients who experienced a hemorrhage, 78 were recorded as receiving a vitamin K antagonist (VKA) and 24 as receiving non-VKA oral anticoagulants (NOAC). Hemoptysis and pulmonary hemorrhage were considered AEs of special interest and are discussed further below.

### *3.3.2. Safety in prevalent vs. incident patients*

A post hoc analysis compared prevalent patients (disease duration  $\geq 6$  months) ( $n = 713$ ) with incident patients (diagnosed within  $< 6$  months of enrollment) ( $n = 197$ ) according to disease duration data available at baseline. Disease characteristics, including 6MWD and WHO FC, indicated a more severe disease status in incident patients compared with prevalent patients (data not shown). Median disease duration was 1.8 (range, 0.0–6.0) months in incident patients and 3.2 (range, 0.5–39.7) years in prevalent patients. AEs were reported in 471 prevalent patients (66.1%) and 119 incident patients (60.4%), and SAEs in 276 (38.7%) and 73 (37.1%) prevalent and incident patients, respectively.

### *3.3.3. Comparison between riociguat-pretreated and riociguat-newly treated patients*

Compared with riociguat-pretreated patients, riociguat-newly treated patients had a numerically shorter disease duration, shorter 6MWD, a higher proportion of WHO FC III/IV disease, and a greater proportion of incident disease (Table 3). More than 90% of patients in both groups had at least one comorbidity. Approximately 89% of riociguat-pretreated patients and 83% of riociguat-newly treated patients completed the study (Figure 3). Of the riociguat-newly treated patients, 72 (17.2%) had switched from previous PAH-approved therapy: 65 (15.5%) from PDE5i, 5 (1.2%) from a prostanoid, and 12 (2.9%) from an ERA (some patients switched from more than one prior therapy).



**Fig. 3.** Disposition of riociguat-pretreated and riociguat-newly treated patients with CTEPH.

Chart shows primary reason for discontinuation.

<sup>a</sup>Other reasons for not completing the study are listed in supplementary Table 1.

**Table 3**

Baseline demographics and disease characteristics of riociguat-pretreated and riociguat-newly treated patients.

	Riociguat-pretreated <sup>a</sup> (n = 537)	Riociguat-newly treated <sup>b</sup> (n = 419)
Age, years	65.9 ± 14.1	66.8 ± 13.3
<b>Age group, years, n (%)</b>		
< 65	218 (40.6)	148 (35.3)
65 to < 75	138 (25.7)	122 (29.1)
≥ 75	181 (33.7)	149 (35.6)
Female sex, n (%)	337 (62.8)	233 (55.6)
BMI, kg/m <sup>2</sup>	29.1 ± 19.5	28.0 ± 6.3
<b>BMI category, kg/m<sup>2</sup>, n (%)</b>		
< 18.5	15 (2.8)	9 (2.1)
18.5 to < 25	164 (30.5)	126 (30.1)
25 to < 30	191 (35.6)	157 (37.5)
≥ 30	167 (31.1)	127 (30.3)
<b>Smoking status, n (%)</b>		
Never	332 (61.8)	270 (64.4)
Former	181 (33.7)	133 (31.7)
Current	24 (4.5)	16 (3.8)

Prevalent (disease duration $\geq 6$ months), n (%)	481 (89.6)	232 (55.4)
Incident (disease duration < 6 months)	28 (5.2)	169 (40.3)
Duration status unknown, n (%)	28 (5.2)	18 (4.3)
Age at initial PH diagnosis, years	61.6 $\pm$ 14.8 (n = 509)	64.2 $\pm$ 13.9 (n = 403)
Median (IQR) PH disease duration, years	2.9 (1.5–5.6)	0.8 (0.2–4.0)
Persistent CTEPH following PEA, n (%)	133 (24.8)	74 (17.7)
Persistent CTEPH following BPA, n (%)	16 (3.0)	10 (2.4)
WHO FC, % (I/II/III/IV/unknown)	5.6/45.1/43.6/2.8/3.0	1.9/29.4/58.5/3.3/6.9
BNP, pg/mL (median, range)	107 (5–3560) (n = 79)	171 (6–5844) (n = 69)
NT-proBNP, pg/mL (median, range)	483 (16–177 759) (n = 320)	813 (17–48 858) (n = 220)
6MWD, m	382 $\pm$ 122 (n = 477)	341 $\pm$ 133 (n = 334)
<b>6MWD, n (%)</b>		
< 320 m <sup>c</sup>	152 (28.3)	138 (32.9)
$\geq 320$ m	325 (60.5)	196 (46.8)
< 380 m	219 (40.8)	202 (48.2)
$\geq 380$ m <sup>c</sup>	258 (48.0)	132 (31.5)
Missing	60 (11.2)	85 (20.3)
EQ-5D VAS	63.6 $\pm$ 19.7 (n = 144)	60.1 $\pm$ 22.1 (n = 85)
Borg Dyspnea Index	3.7 $\pm$ 2.2 (n = 403)	4.0 $\pm$ 2.3 (n = 298)
mPAP, mmHg	43.3 $\pm$ 11.8 (n = 462)	42.8 $\pm$ 11.2 (n = 388)
PVR, dyn·s·cm <sup>-5</sup>	675 $\pm$ 575 (n = 413)	626 $\pm$ 400 (n = 354)
PAWP, mmHg	11.2 $\pm$ 5.0 (n = 436)	10.9 $\pm$ 4.9 (n = 373)
Cardiac index, L/min/m <sup>2</sup>	2.8 $\pm$ 5.0 (n = 409)	2.7 $\pm$ 3.7 (n = 347)
RAP, mmHg	9.3 $\pm$ 5.9 (n = 389)	8.6 $\pm$ 5.1 (n = 321)
SvO <sub>2</sub> (%)	63.6 $\pm$ 9.5 (n = 323)	63.9 $\pm$ 8.9 (n = 290)
<b>Riociguat daily dose at initial study visit, mg</b>		
Mean	7.1 $\pm$ 1.1	6.6 $\pm$ 1.6 (n = 397)
Median (range)	7.5 (1.5–7.5)	7.5 (1.5–7.5) (n = 397)
<b>Riociguat median daily dose at initial study visit, mg, n (%)</b>		
$\leq 2.5$	6 (1.1)	7 (1.7)
> 2.5 to 4.5	34 (6.3)	74 (17.7)
> 4.5 to 6	51 (9.5)	39 (9.3)
> 6 to 7.5	446 (83.1)	277 (66.1)
Missing	0	22 (5.3)
<b>PAH-approved regimen at initial study visit, n (%)</b>		
Riociguat monotherapy <sup>d</sup>	403 (75.1)	355 (84.7)
	134 (25.0)	64 (15.3)

Riociguat combination therapy <sup>e,f</sup>	112 (20.9)	58 (13.8)
Riociguat + ERA	21 (3.9)	15 (3.6)
Riociguat + ambrisentan	47 (8.8)	20 (4.8)
Riociguat + bosentan	44 (8.2)	23 (5.5)
Riociguat + macitentan	6 (1.1)	3 (0.7)
Riociguat + prostanoid	3 (0.6)	3 (0.7)
Riociguat + iloprost	2 (0.4)	0 (0.0)
Riociguat + intravenous treprostinil	1 (0.2)	0 (0.0)
Riociguat + intravenous epoprostenol	16 (3.0)	3 (0.7)
Riociguat + ERA + prostanoid		
Concomitant CCB, n (%)	13 (2.4)	9 (2.1)
<b>Concomitant anticoagulation, n (%)</b>		
Oral anticoagulation	482 (89.8)	379 (90.5)
Vitamin K antagonist	311 (57.9)	195 (46.5)
Direct oral anticoagulant	84 (15.6)	106 (25.3)
Other oral anticoagulation <sup>g</sup>	87 (16.2)	72 (17.2)
Other anticoagulant <sup>g</sup>	34 (6.3)	32 (7.6)
Concomitant antiplatelet agents, n (%)	16 (3.0)	28 (6.7)
<b>Comorbidity, n (%)</b>		
At least one medical history finding	509 (94.8)	392 (93.6)
Arterial hypertension	231 (43.0)	214 (51.1)
Venous thromboembolism	223 (41.5)	208 (49.6)
Thyroid disease	100 (18.6)	83 (19.8)
Cancer	67 (12.5)	56 (13.4)
Coronary heart disease	67 (12.5)	55 (13.1)
Diabetes mellitus	66 (12.3)	57 (13.6)
Obstructive sleep apnea	65 (12.1)	34 (8.1)
History of hemoptysis/lung bleeding	23 (4.3)	14 (3.3)
Other	428 (79.7)	331 (79.0)

6MWD, 6-minute walking distance; BMI, body mass index; BNP, brain natriuretic peptide;

BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CTEPH, chronic

thromboembolic pulmonary hypertension; EQ-5D VAS, EuroQoL 5-dimensional Visual

Analog Score; ERA, endothelin receptor antagonist; IQR, interquartile range; mPAP, mean

pulmonary artery pressure; NT-proBNP, N-terminal prohormone of brain natriuretic peptide;

PAH, pulmonary arterial hypertension; PAWP, pulmonary artery wedge pressure; PEA,

pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular

resistance; RAP, right atrial pressure; SD, standard deviation; SvO<sub>2</sub>, saturated venous

oxygen; WHO FC, World Health Organization functional class.

Data are mean ± SD or number (%), unless otherwise stated.

<sup>a</sup>Receiving riociguat for ≥ 3 months before entry (n = 537 unless otherwise indicated).

<sup>b</sup>Receiving riociguat for < 3 months before entry (n = 419 unless otherwise indicated).

<sup>c</sup>Thresholds chosen (380 m prespecified) based on available (6MWD) cohort data at the time indicating good or poor prognosis in PAH.

<sup>d</sup>Patients receiving riociguat but no ERA or prostanoid.

<sup>e</sup>Patients receiving riociguat + ERA or prostanoid or both.

<sup>f</sup>No patient received concomitant PDE5i during the study.

<sup>g</sup>As indicated by the investigator on the CRF.

AEs were reported in 270 riociguat-newly treated patients (64.4%) and 345 riociguat-pretreated patients (64.2%). SAEs were reported in 166 riociguat-newly treated patients (39.6%) and 199 riociguat-pretreated patients (37.1%). Numerically more AEs and SAEs in riociguat-newly treated patients were considered drug-related and led to drug discontinuation than in riociguat-pretreated patients (Table 4). The types of AEs and SAEs were generally similar between the two groups. The most common AEs or SAEs leading to discontinuation are shown in supplementary Table 4. Safety results in switched patients were generally similar to those in non-switched patients (data not shown). In riociguat-pretreated and riociguat-newly treated patients, AEs and SAEs were more frequent with combination therapy than with monotherapy (supplementary Table 5).

**Table 4**

Safety summary in riociguat-pretreated and riociguat-newly treated patients with CTEPH.

	Riociguat-pretreated <sup>a</sup> (n = 537)	Riociguat-newly treated <sup>b</sup> (n = 419)
<b>AEs</b>	<b>n (%)</b>	<b>n (%)</b>
Any AE	345 (64.2)	270 (64.4)
<b>Most common AEs<sup>c</sup></b>	<b>n (%)</b>	<b>n (%)</b>
Peripheral edema/edema	73 (13.6) <sup>d</sup>	39 (9.3) <sup>e</sup>
Dyspnea	50 (9.3)	31 (7.4)
Dizziness	42 (7.8)	30 (7.2)
RV failure/cardiac failure	40 (7.4) <sup>f</sup>	34 (8.1) <sup>g</sup>
Pneumonia	31 (5.8)	17 (4.1)
Cough	27 (5.0)	16 (3.8)
Hypotension	13 (2.4)	24 (5.7)
Dyspepsia	12 (2.2)	21 (5.0)



<i>Any drug-related AE<sup>h</sup></i>	53 (9.9)	95 (22.7)
<i>Discontinuation due to AE</i>	21 (3.9)	34 (8.1)
<b>SAEs</b>	<b>n (%)</b>	<b>n (%)</b>
Any SAE	199 (37.1)	166 (39.6)
<b>Most common SAEs<sup>i</sup></b>	<b>n (%)</b>	<b>n (%)</b>
RV failure/cardiac failure	39 (7.3) <sup>j</sup>	32 (7.6) <sup>k</sup>
Pneumonia	26 (4.8)	13 (3.1)
Dyspnea	17 (3.2)	17 (4.1)
Syncope	14 (2.6)	10 (2.4)
PH <sup>l</sup>	15 (2.8)	7 (1.7)
Pulmonary embolism	3 (0.6)	9 (2.1)
<i>Any drug-related SAE<sup>h</sup></i>	13 (2.4)	21 (5.0)
<i>Discontinuation due to SAE</i>	17 (3.2)	21 (5.0)

AE, adverse event; PH, pulmonary hypertension; RV, right ventricular; SAE, serious adverse event.

<sup>a</sup>Receiving riociguat for  $\geq 3$  months before entry. Median (range) duration of observation and riociguat treatment (days): 532.0 (0.0–1346.0); 506.0 (0.0–1346.0).

<sup>b</sup>Receiving riociguat for  $< 3$  months before entry. Median (range) duration of observation and riociguat treatment (days): 475.0 (0.0–1367.0); 455.0 (0.0–1367.0).

<sup>c</sup>Preferred-term AEs reported in  $\geq 5\%$  of patients in either group.

<sup>d</sup>Including peripheral edema in 46 patients (8.6%) and edema in 30 patients (5.6%).

<sup>e</sup>Including peripheral edema in 27 patients (6.4%) and edema in 12 patients (2.9%).

<sup>f</sup>Including RV failure in 34 patients (6.3%) and cardiac failure in 7 patients (1.3%).

<sup>g</sup>Including RV failure in 27 patients (6.4%) and cardiac failure in 9 patients (2.1%).

<sup>h</sup>Investigator's causality assessment.

<sup>i</sup>Preferred-term SAEs reported in  $\geq 2\%$  of patients in either group.

<sup>j</sup>Including RV failure in 34 patients (6.3%) and cardiac failure in 6 patients (1.1%).

<sup>k</sup>Including RV failure in 25 patients (6.0%) and cardiac failure in 9 patients (2.1%).

<sup>l</sup>Preferred term for worsening of the condition.

Note. Patients with peripheral edema/edema or RV failure/cardiac failure could have both events.



### 3.4. AEs and SAEs of special interest

In general, AEs and SAEs of special interest were infrequent (Table 5). All of the 16 patients with serious hemoptysis/pulmonary hemorrhage overall were recorded as receiving concomitant anticoagulants, three as receiving concomitant antiplatelet therapy, and one as receiving a concomitant prostanoid. The incidence of hypotension was low across all subgroups (supplementary Table 6).

**Table 5**

AEs and SAEs of special interest.

	All CTEPH (n = 956) <sup>a</sup>	Riociguat- pretreated <sup>b</sup> (n = 537)	Riociguat- newly treated <sup>c</sup> (n = 419)
<b>Absolute AE rates, n (%)</b>			
Hypotension	37 (3.9)	13 (2.4)	24 (5.7)
Hemoptysis/pulmonary hemorrhage	26 (2.7)	15 (2.8)	11 (2.6)
<b>Exposure-adjusted AE rates (95% CI)<sup>d</sup></b>			
Hypotension	2.7 (2.0–3.7)	1.7 (0.9–2.7)	4.3 (2.8–6.2)
Hemoptysis/pulmonary hemorrhage	2.2 (1.5–3.0)	1.9 (1.1–3.0)	2.6 (1.5–4.1)
<b>Absolute SAE rates, n (%)</b>			
Hypotension	4 (0.4)	3 (0.6)	1 (0.2)
Hemoptysis/pulmonary hemorrhage	16 (1.7)	8 (1.5)	8 (1.9)
<b>Exposure-adjusted SAE rates (95% CI)<sup>d</sup></b>			
Hypotension	0.3 (0.1–0.7)	0.4 (0.1–0.9)	0.2 (0.0–0.8)
Hemoptysis/pulmonary hemorrhage	1.4 (0.9–2.1)	1.1 (0.5–1.9)	1.9 (1.0–3.2)

AE, adverse event; CI, confidence interval; CTEPH, chronic thromboembolic pulmonary

hypertension; SAE, serious adverse event.

<sup>a</sup>Median (range) duration of observation and riociguat treatment (days): 504.0 (0.0–1367.0); 493.5 (0.0–1367.0).

<sup>b</sup>Receiving riociguat for  $\geq 3$  months before entry. Median (range) duration of observation and riociguat treatment (days): 532.0 (0.0–1346.0); 506.0 (0.0–1346.0).

<sup>c</sup>Receiving riociguat for  $< 3$  months before entry. Median (range) duration of observation and riociguat treatment (days): 475.0 (0.0–1367.0); 455.0 (0.0–1367.0).

<sup>d</sup>Rate per 100 patient-years, calculated by the number of events observed divided by (total drug exposure in years/100).

### 3.5. AEs associated with PEA or BPA

In total, 47 patients (4.9%) underwent PEA (one operation in 44 patients [4.6%] and two operations in three patients [0.3%]). Within 10 days after PEA, nine of these patients (19.1%) had an AE, six (12.8%) had an SAE, and one (2.1%) had an AE-related death. No episode of hemoptysis was reported within 10 days following PEA. Also, 89 patients (9.3%) underwent BPA (mean:  $2.1 \pm 1.4$  sessions; median: 2; range: 1–8) during the study. Within 10 days after BPA, six of these patients (6.7%) had an AE and six (6.7%) had an SAE. No AE-related deaths were reported. The AEs included hemoptysis in two patients. Both events resolved, and neither was considered related to riociguat. None of the AEs reported within 10 days after PEA or BPA was considered related to riociguat.

### 3.6. Efficacy assessments


Results for indicators of efficacy (6MWD, Borg Dyspnea Index, EQ-5D VAS, hemodynamic measurements, and biomarkers) have not been the focus of this non-interventional study; many data were missing, and values varied greatly between patients. Selection bias for repeat efficacy assessments could confound the results. These results are therefore not shown or discussed here.

### 3.7. Deaths and fatal SAEs

Of the 956 patients with CTEPH, 101 (10.6%) (44 riociguat-newly treated patients [10.5%] and 57 riociguat-pretreated patients [10.6%]) died or experienced an SAE with a fatal outcome with onset during the study. Of these SAEs, 93 (9.7% of patients) began during the treatment phase: 38 in riociguat-newly treated patients (9.1%) and 55 in riociguat-pretreated patients (10.2%). Fatal SAEs with post-treatment onset occurred in six riociguat-newly treated patients (1.4%) and two riociguat-pretreated patients (0.4%). The most

common fatal SAEs in the total CTEPH population were RV failure/cardiac failure in 27 patients (2.8%), followed by cardiac arrest, pneumonia, sepsis, and hemoptysis, each in three patients (0.3%). In 19 patients (2.0%), the SAE was listed as death (cause unknown). Two deaths were considered related to riociguat by the investigator. In one case the cause of death was hemoptysis, which occurred more than 2 years after therapy was initiated in a patient receiving concurrent anticoagulant medication. The other case was death from RV failure/cardiac failure, which occurred 10 days after the last dose of riociguat and was attributed to lack of efficacy of riociguat rather than an AE of the drug.

Estimated survival rates in the total CTEPH population at 1, 2, and 3 years were 94.7% (95% CI, 92.9–96.0%), 85.7% (95% CI, 82.4–88.4%), and 79.3% (95% CI, 74.0–83.6%), respectively. Kaplan–Meier survival curves for riociguat-newly treated and riociguat-pretreated patients are shown in Figure 4.



**Fig. 4.** Kaplan–Meier survival curves for riociguat-newly treated and riociguat-pretreated patients.

CI, confidence interval.

In the post hoc analysis assessing patients according to disease duration, death during the treatment period occurred in 77 prevalent patients (10.8%) and 14 incident patients (7.1%). Four prevalent patients (0.6%) and 4 incident patients (2.0%) died during the 30-day safety follow-up.

## Discussion

### 4.1. Safety findings

EXPERT provided data on the safety and tolerability of riociguat in more than 950 patients with CTEPH in real-world clinical practice. The types of AEs observed were consistent with those reported in Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial-1 (CHEST-1) [14], CHEST-2 [15, 17], and the CTEPH Early Access Study [18], with no new safety signals identified. The most common events (e.g., peripheral edema/edema, dizziness, and dyspnea) were consistent with symptoms of the underlying disease or with vasodilatation by riociguat. Although the numbers of patients undergoing BPA or PEA were small, there was no evidence of an increased risk of drug-related events shortly after these procedures. The exposure-adjusted rate of hypotension (2.7 events per 100 patient-years) was lower than that reported in CHEST-2 (4.0 events per 100 patient-years) [15]. The rates of hemoptysis/pulmonary hemorrhage were similar (2.2 and 2.8 events per 100 patient-years in EXPERT and CHEST-2 [15] respectively). Most patients were receiving anticoagulants as required by CTEPH treatment guidelines: these may have contributed to the bleeding AEs. A separate publication comparing hemorrhagic and thrombotic/embolic events in patients receiving VKAs or NOACs at baseline is in preparation. In patients receiving riociguat as part of a combination regimen, the incidences of AEs and SAEs were higher than in patients receiving monotherapy. These data should be

interpreted with caution as they are descriptive, they are not adjusted for differences between the combination and monotherapy groups, they refer to treatment at baseline, and the numbers of patients receiving prostanoids were small. Clinical experience with riociguat shows an increased frequency of some AEs such as hypotension, dizziness, and edema during dose adjustment [19, 20]. These effects, described in the reference safety information for the drug, have been attributed to the vasodilatory properties of riociguat [19]. Although the overall frequency of AEs or SAEs did not differ greatly between riociguat-newly treated and riociguat-pretreated patients, numerically more events of hypotension were reported in newly treated patients, as was discontinuation because of AEs or SAEs. The higher frequency of hypotension might be partly explained by a more severe disease state (as indicated by 6MWD and WHO FC) and partly by more frequent monitoring during dose-adjustment periods. For riociguat-pretreated patients, bias may be introduced, because those who had to discontinue the drug because of AEs, or who died, could not be documented in the study. Patients enrolled in disease registries as prevalent cases may be more likely to have stable disease than incident patients [21]. In our post hoc analysis, rates of AEs and SAEs were similar between prevalent and incident patients, indicating that the higher proportion of incident patients in the riociguat-newly treated group did not disadvantage them in terms of safety. There is no explanation for the greater number of deaths in prevalent patients than incident patients but it may be related to the longer CTEPH disease duration in the prevalent group.

#### *4.2. Comparison with other studies*

Compared with the 247 non-operable patients described in the international prospective CTEPH registry [8, 22], CTEPH patients in EXPERT had less severe functional impairment, with 53.1% categorized as WHO FC III/IV at baseline versus 83.0% and a slightly higher mean 6MWD at baseline (365 vs. 315 m). The international registry enrolled only incident patients, whereas 74.6% of patients with CTEPH in EXPERT had prevalent disease. In a

prospective study of 392 patients newly diagnosed with CTEPH in Germany, riociguat was the initial treatment in 81.1% of patients who received medical therapy, illustrating the importance of obtaining safety data for riociguat [23]. The patients in this study had generally similar characteristics to those in the EXPERT population.

The estimated survival rate in patients with CTEPH in EXPERT (94.7%, 85.7%, and 79.3% at 1, 2, and 3 years, respectively) appears to be higher than in non-operable patients in the international CTEPH registry (88%, 79%, and 70% at 1, 2, and 3 years, respectively) [22], non-PEA patients in the Giessen registry (84.5% at 1 year and 72.5% at 3 years) [24], US veterans evaluated in a retrospective analysis (89.2%, 81.4%, and 72.7% at 1, 3, and 5 years, respectively) [25], and patients in several other registries [12, 13, 24, 26–28]. In an analysis from COMPERA, 561 medically treated patients with CTEPH were graded as at low, intermediate, or high risk for death based on their WHO FC, 6MWD, BNP/NT-proBNP, RAP, CI, and SVO<sub>2</sub> [29]. The estimated 1-year survival rate was 98.6%, 94.9%, and 75.5% in the low-, intermediate-, and high-risk groups, respectively. The baseline characteristics of CTEPH patients in EXPERT and their estimated survival were closest to those of the intermediate-risk COMPERA group.

Registries provide important information about the safety of drugs in clinical practice and thus supplement the information gained from selected populations under the closely controlled conditions of clinical trials. They may also detect previously unsuspected safety signals. No such signals were identified in EXPERT. Limitations inherent in registries including confounding, lack of randomization, missing values, and the hazards of generalizing data from the registry population to other populations [30], also apply to EXPERT. In addition, EXPERT was designed to collect safety information on riociguat; it was not designed to provide data on the long-term efficacy of this drug. Strengths of EXPERT include the relatively long observation time (median: 504 days), the large number (956) of patients with CTEPH, the large proportion of patients completing the study. The planned enrollment for the entire study was 900 patients to allow for detection of

≥ 3 “uncommon” AEs with an incidence ≥ 0.5%. Given that 956 patients with CTEPH were enrolled, there were enough patients in the CTEPH cohort alone to achieve this power level. The availability of safety data in patients receiving riociguat either as monotherapy or as part of a combination regimen at baseline was also a strength of the study.

## **Conclusion**

Final data from the EXPERT registry showed that in patients with CTEPH, the long-term safety of riociguat in routine practice, was consistent with clinical trials, with no new safety concerns identified.

## **Acknowledgements and funding**

The EXPERT registry was funded by Bayer AG (Berlin, Germany) and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

The authors acknowledge the database administration by Torsten Tille, Dresden, and the project administration of Mrs Romy Hoppenz and Mrs Linda Kottke at GWT-TUD GmbH, Dresden.

Medical writing services provided by Richard Murphy PhD of Adelphi Communications Ltd, Macclesfield, UK were funded by Bayer AG in accordance with Good Publication Practice (GPP3) guidelines.

## References

- [1] N. Galiè, et al., 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) International Society for Heart and Lung Transplantation (ISHLT), *Eur Respir J.* 46.(4) (2015) 903-975.
- [2] G. Simonneau, et al., Updated clinical classification of pulmonary hypertension, *J Am Coll Cardiol.* 62 (Suppl 25) (2013) D34-D41.
- [3] N.H. Kim, et al., Chronic thromboembolic pulmonary hypertension, *J Am Coll Cardiol.* 62 (25 Suppl) (2013) D92-D99.
- [4] P. Fedullo, et al., Chronic thromboembolic pulmonary hypertension, *Am J Respir Crit Care Med.* 183 (12) (2011) 1605-1613.
- [5] E. Mayer, et al., Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry, *J Thorac Cardiovasc Surg.* 141 (3) (2011) 702-710.
- [6] D. Jenkins, Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension, *Eur Respir Rev.* 24 (136) (2015) 263-271.
- [7] D. Jenkins, et al., Pulmonary endarterectomy in the management of chronic thromboembolic pulmonary hypertension, *Eur Respir Rev.* 26 (143) (2017).
- [8] J. Pepke-Zaba, et al., Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry, *Circulation.* 124 (18) (2011) 1973-1981.
- [9] D. Jenkins, et al., State-of-the-art chronic thromboembolic pulmonary hypertension diagnosis and management, *Eur Respir Rev.* 21 (123) (2012) 32-39.
- [10] D.H. Freed, et al., Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension, *J Thorac Cardiovasc Surg.* 141 (2) (2011) 383-387.
- [11] E. Mayer, Surgical and post-operative treatment of chronic thromboembolic pulmonary hypertension, *Eur Respir Rev.* 19 (115) (2010) 64-67.
- [12] J. Hurdman, et al., ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre, *Eur Respir J.* 39 (4) (2012) 945-955.
- [13] J.E. Cannon, et al., Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy: results from the UK national cohort, *Circulation.* 133 (18) (2016) 1761-1771.
- [14] H.A. Ghofrani, et al., Riociguat for the treatment of chronic thromboembolic pulmonary hypertension, *N Engl J Med.* 369 (4) (2013) 319-329.
- [15] G. Simonneau, et al., Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial, *Lancet Respir Med.* 4 (5) (2016) 372-380.



- [16] N.H. Kim, et al., Chronic thromboembolic pulmonary hypertension, *Eur Respir J.* 53 (1) (2019).
- [17] G. Simonneau, et al., Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2), *Eur Respir J.* 45 (5) (2015) 1293-1302.
- [18] V. McLaughlin, et al., Riociguat in patients with chronic thromboembolic pulmonary hypertension: Results from an early access study, *BMC Pulm Med.* 17 (1) (2017) 216-224.
- [19] Bayer-AG, Adempas. Summary of Product Characteristics., European Medicines Agency website. Available from: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/002737/WC500165034.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002737/WC500165034.pdf) [cited 2019 May 22nd]
- [20] Bayer Pharma AG, US prescribing information: ADEMPAS (riociguat) tablets, for oral use, 2017.
- [21] M. Humbert, et al., Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension, *Eur Respir J.* 36 (3) (2010) 549-555.
- [22] M. Delcroix, et al., Long-term outcome of patients with chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry, *Circulation.* 133 (2016) 859-871.
- [23] T. Kramm, et al., Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany, *Clin Res Cardiol.* 107 (7) (2018) 548-553.
- [24] H. Gall, et al., The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups, *J Heart Lung Transplant.* (2017) S1053-S2498.
- [25] A.W. Trammell, et al., EXPRESS: Mortality in U.S. veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors, *Pulm Circ.* (2019) 2045894019825763.
- [26] P. Escribano-Subias, et al., Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective, *Int J Cardiol.* 203 (2016) 938-944.
- [27] S. Mueller-Mottet, et al., Long-term data from the Swiss pulmonary hypertension registry, *Respiration.* 89 (2) (2015) 127-140.
- [28] R. Condliffe, et al., Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension, *Am J Respir Crit Care Med.* 177 (10) (2008) 1122-1127.
- [29] M. Delcroix, et al., Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients, *Eur Respir J.* 52 (5) (2018).
- [30] M.D. McGoon, et al., Pulmonary arterial hypertension: epidemiology and registries, *J Am Coll Cardiol.* 62 (25 Suppl) (2013) D51-D59.

Riociguat is approved for treatment of chronic thromboembolic pulmonary hypertension (CTEPH).

The EXPERT study evaluated the safety of riociguat in clinical practice.

Results are available for 956 CTEPH patients in 28 countries, followed for 1–4 years.

The safety of riociguat in clinical practice was consistent with clinical trials.

No new safety concerns were identified.

The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. Information on the safety of riociguat in clinical practice could complement the results obtained in these trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) was an international, multicenter, prospective, uncontrolled, non-interventional cohort study designed to obtain this information.

EXPERT was the largest study of its kind in patients receiving riociguat for the treatment of CTEPH. It was performed in 28 countries in Europe, Canada, Latin America, and the Middle East. Patients pretreated or newly treated with riociguat, alone or in combination with PAH-approved therapies, were eligible for inclusion.

This paper describes the final EXPERT data for patients with CTEPH (n=956). Patients were followed from 1 to 4 years from enrolment, and approximately 86% of patients completed the study, producing a substantial safety database. Data are presented for adverse events (AEs), serious AEs, AEs of special interest (hypotension and hemoptysis/pulmonary haemorrhage), and estimated survival in pretreated and newly treated patients. These results showed that the safety of riociguat in clinical practice in patients with CTEPH was consistent with the clinical trials, with no new safety concerns identified. The most common types of AE observed were consistent with the underlying disease or the known pharmacological effects of riociguat. The exposure-adjusted rate of hemoptysis/pulmonary hemorrhage was comparable to the long-term extension of the Phase 3 trial of riociguat in CTEPH. Riociguat is the only medical therapy currently licensed for the treatment of CTEPH: the results are therefore relevant to all clinicians involved in the pharmacological management of this condition. Our results could aid clinicians in making decisions about the use of riociguat in a broad population of patients with CTEPH.

Jorge Caneva  
Pneumology Service  
Hospital Universitario Fundación Favaloro  
Buenos Aires  
Argentina

Graciela Tuhay  
Pneumology Service  
Hospital Universitario Fundación Favaloro  
Buenos Aires  
Argentina

Mirta Diez  
Clinical Cardiology Service  
ICBA - Instituto Cardiovascular de Buenos Aires  
Buenos Aires  
Argentina

Maria Lujan Talavera  
Clinical Cardiology Service  
ICBA - Instituto Cardiovascular de Buenos Aires  
Buenos Aires  
Argentina

Adriana Acosta  
Clinical Cardiology Service  
ICBA - Instituto Cardiovascular de Buenos Aires  
Buenos Aires  
Argentina

Norberto Vulcano  
Department of Cardiology  
Hospital Italiano de Buenos Aires  
Buenos Aires  
Argentina

Martin Bosio  
Center for Respiratory Medicine  
Hospital Británico  
Buenos Aires  
Argentina

Lorena Maldonado  
Center for Respiratory Medicine  
Hospital Británico  
Buenos Aires  
Argentina

Sabino Deleo  
Pneumology  
Cen Asma Centro de Enfermedades Respiratorias

Buenos Aires  
Argentina

Luciano Melatini  
Pneumology  
Instituto Diagnostico  
Buenos Aires  
Argentina

Anne Keogh  
Heart Lung Clinic  
St Vincent's Hospital Sydney  
Darlinghurst  
New South Wales  
Australia

Eugene Kotlyar  
Heart Lung Clinic  
St Vincent's Hospital Sydney  
Darlinghurst  
New South Wales  
Australia

John Feenstra  
Queensland Lung Transplant Service (QLTS)  
Prince Charles Hospital  
Chermside  
QLD  
Australia

Nathan Dwyer  
Department of Cardiology  
Royal Hobart Hospital  
Hobart  
Tasmania  
Australia

Heath Adams  
Department of Cardiology  
Royal Hobart Hospital  
Hobart  
Tasmania  
Australia

Wendy Stevens  
Rheumatology Department  
St Vincent's Hospital  
Melbourne  
Victoria  
Australia

Peter Steele  
Clinical Trials Centre  
Cardiology Service  
Royal Adelaide Hospital  
Adelaide  
South Australia  
Australia

Susanna Proudman  
Clinical Trials Centre  
Cardiology Service  
Royal Adelaide Hospital  
Adelaide  
South Australia  
Australia

Robert Minson  
Flinders Cardiac Clinic  
Flinders Medical Centre  
Bedford Park  
South Australia  
Australia

Glenn Reeves  
Immunology Department  
John Hunter Hospital  
Newcastle  
New South Wales  
Australia

Melanie Lavender  
Advanced Lung Disease Unit  
Fiona Stanley Hospital  
Murdoch  
Western Australia  
Australia

Benjamin Ng  
Nepean Hospital  
Kingswood  
New South Wales  
Australia

Michele Mackenzie  
Nepean Hospital  
Kingswood  
New South Wales  
Australia

Lisa Barry  
Nepean Hospital

Kingswood  
New South Wales  
Australia

Margarethe Gruenberger  
Servicestelle für klinische Studien  
Krankenhaus der Elisabethinen Linz GmbH  
Linz  
Austria

Charlotte Huber  
Servicestelle für klinische Studien  
Krankenhaus der Elisabethinen Linz GmbH  
Linz  
Austria

Irene Lang  
Clinical Department of Cardiology  
Medical University of Vienna  
Vienna  
Austria

Ioana Tilea  
Clinical Department of Cardiology  
Medical University of Vienna  
Vienna  
Austria

Roela Sadushi-Kolici  
Clinical Department of Cardiology  
Medical University of Vienna  
Vienna  
Austria

Judith Löffler-Ragg  
Department of Internal Medicine II  
Medical University of Innsbruck  
Innsbruck  
Austria

Lisa-Theresa Feistmantl  
Department of Internal Medicine II  
Medical University of Innsbruck  
Innsbruck  
Austria

Patrick Evrard  
Department of Intensive Care  
Centre Hospitalier Université Dinant-Mont-Godinne  
Yvoir  
Belgium

Renaud Louis  
Department of Pulmonary Medicine  
Centre Hospitalier Université Liège  
Liège  
Belgium

Julien Guiot  
Department of Pulmonary Medicine  
Centre Hospitalier Université Liège  
Liège  
Belgium

Marco Naldi  
Department of Pulmonary Medicine  
Centre Hospitalier Université Liège  
Liège  
Belgium

Michel De Pauw  
Department of Internal Medicine and Pediatrics  
Ghent University Hospital  
Ghent  
Belgium

Sanjay Mehta  
Centre for Critical Illness Research  
Lawson Health Research Institute  
London  
Ontario  
Canada

Rafael Conde Camacho  
Internal Medicine and Pneumology  
Fundación Neumológica  
Bogotá  
Colombia

Patricia Parada Tovar  
Internal Medicine and Pneumology  
Fundación Neumológica  
Bogotá  
Colombia

Alejandro Londoño  
Pneumology Department  
Clínica Cardio VID  
Medellin  
Colombia



Felipe Campo  
Pneumonology Department  
Clínica Cardio VID  
Medellin  
Colombia

Paula Garcia  
Pneumonology Department  
Clínica Cardio VID  
Medellin  
Colombia

Camila Lema  
Pneumonology Department  
Clínica Cardio VID  
Medellin  
Colombia

Mauricio Orozco-Levi  
Pneumonology Service  
Fundación Cardiovascular de Colombia  
Floridablanca  
Santander  
Colombia

William Martinez  
Valle de Lili Foundation  
Cali  
Colombia

Juan Esteban Gomez  
Valle de Lili Foundation  
Cali  
Colombia

Jens Erik Nielsen-Kudsk  
Department of Clinical Medicine  
Aarhus University Hospital Skejby  
Aarhus  
Denmark

Soren Mellemkjaer  
Department of Clinical Medicine  
Aarhus University Hospital Skejby  
Aarhus  
Denmark

Ly Anton  
Centre of Cardiology  
North Estonia Medical Centre Foundation  
Tallinn

Estonia

Alan Altraja  
Department of Pulmonology  
Tartu University Hospital  
Tartu  
Estonia

Tapani Vihinen  
Heart Center  
Sydänkeskus Turku University Hospital  
Turku  
Finland

Tuija Vasankari  
Heart Center  
Sydänkeskus Turku University Hospital  
Turku  
Finland

Olivier Sitbon  
Hôpital Bicêtre  
Le Kremlin-Bicêtre  
France

Vincent Cottin  
National Reference Centre for Rare Pulmonary Diseases  
Hôpital Louis Pradel  
Lyon  
France

Laurent Têtu  
Pneumology Service  
Hôpital Larrey  
Toulouse  
France

Elise Noël-Savina  
Pneumology Service  
Hôpital Larrey  
Toulouse  
France

Nicole Shearman  
Department of Respiratory Medicine and the German Center for Lung Research  
Hannover Medical School  
Hannover  
Germany

Susanne Tayler  
Department of Respiratory Medicine and the German Center for Lung Research

Hannover Medical School  
Hannover  
Germany

Ilona Olzik  
Department of Respiratory Medicine and the German Center for Lung Research  
Hannover Medical School  
Hannover  
Germany

Christine Kulka  
Department of Pneumology  
University Hospital Carl Gustav Carus  
Dresden  
Germany

Jan Grimminger  
Department of Pneumology  
University Medical Center Hamburg-Eppendorf  
Hamburg  
Germany

Marcel Simon  
Department of Pneumology  
University Medical Center Hamburg-Eppendorf  
Hamburg  
Germany

Anna Nolde  
Department of Pneumology  
University Medical Center Hamburg-Eppendorf  
Hamburg  
Germany

Tim Oqueka  
Department of Pneumology  
University Medical Center Hamburg-Eppendorf  
Hamburg  
Germany

Lars Harbaum  
Department of Pneumology  
University Medical Center Hamburg-Eppendorf  
Hamburg  
Germany

Benjamin Egenlauf  
Centre for Pulmonary Hypertension  
Thoraxklinik at Heidelberg University Hospital  
Heidelberg  
Germany

Ralf Ewert  
Department of Internal Medicine  
Clinic and Polyclinic for Internal Medicine B  
Greifswald  
Germany

Christian Schulz  
Department of Internal Medicine II  
Division of Pneumology  
University Medical Center  
Regensburg  
Germany

Sabine Regotta  
Department of Internal Medicine II  
Division of Pneumology  
University Medical Center  
Regensburg  
Germany

Tilmann Kramer  
Department III of Internal Medicine and Cologne Cardiovascular Research Center (CCRC)  
Cologne University Heart Center  
Cologne  
Germany

Susanne Knoop-Busch  
Department III of Internal Medicine and Cologne Cardiovascular Research Center (CCRC)  
Cologne University Heart Center  
Cologne  
Germany

Felix Gerhardt  
Department III of Internal Medicine and Cologne Cardiovascular Research Center (CCRC)  
Cologne University Heart Center  
Cologne  
Germany

Stavros Konstantinides  
Center for Thrombosis and Hemostasis  
University Medical Center of the Johannes Gutenberg University  
Mainz  
Germany

Georgia Pitsiou  
Respiratory Insufficiency Unit  
“G. Papanikolaou” General Hospital of Thessaloniki  
Thessaloniki  
Greece

Ioannis Stanopoulos  
Respiratory Insufficiency Unit  
“G. Papanikolaou” General Hospital of Thessaloniki  
Thessaloniki  
Greece

Evdokia Sourla  
Respiratory Insufficiency Unit  
“G. Papanikolaou” General Hospital of Thessaloniki  
Thessaloniki  
Greece

Sofia Mouratoglou  
Department of Cardiology I  
Aristotle University of Thessaloniki  
Thessaloniki  
Greece

Haralambos Karvounis  
Department of Cardiology I  
Aristotle University of Thessaloniki  
Thessaloniki  
Greece

Athanasios Pappas  
Second Department of Critical Care  
University Hospital Attikon  
National and Kapodistrian University of Athens  
Athens  
Greece

Dimitrios Georgopoulos  
Department of Intensive Care Medicine  
University Hospital of Heraklion  
Heraklion  
Greece

Michail Fanaridis  
Department of Intensive Care Medicine  
University Hospital of Heraklion  
Heraklion  
Greece

Ioanna Mitrouska  
Department of Intensive Care Medicine  
University Hospital of Heraklion  
Heraklion  
Greece

Lampros Michalis  
2nd Department of Cardiology

University Hospital of Ioannina  
Ioannina  
Greece

Konstantinos Pappas  
Division of Cardiology  
University Hospital of Ioannina  
Ioannina  
Greece

Anna Kotsia  
Division of Cardiology  
University Hospital of Ioannina  
Ioannina  
Greece

Sean Gaine  
National Pulmonary Hypertension Unit  
Mater Misericordiae University Hospital  
Dublin  
Ireland

Carmine Dario Vizza  
Policlinico Umberto I  
Department of Cardiovascular, Respiratory, Nephrological, Anaesthesiological, and Geriatric Sciences  
La Sapienza Hospital  
Rome  
Italy

Giovanna Manzi  
Policlinico Umberto I  
Department of Cardiovascular, Respiratory, Nephrological, Anaesthesiological, and Geriatric Sciences  
La Sapienza Hospital  
Rome  
Italy

Roberto Poscia  
Policlinico Umberto I  
Department of Cardiovascular, Respiratory, Nephrological, Anaesthesiological, and Geriatric Sciences  
La Sapienza Hospital  
Rome  
Italy

Roberto Badagliacca  
Policlinico Umberto I  
Department of Cardiovascular, Respiratory, Nephrological, Anaesthesiological, and Geriatric Sciences  
La Sapienza Hospital  
Rome  
Italy

Piergiuseppe Agostoni  
Monzino Cardiology Center Hospital  
Milan  
Italy

Noemi Bruno  
Monzino Cardiology Center Hospital  
Milan  
Italy

Stefania Farina  
Monzino Cardiology Center Hospital  
Milan  
Italy

Michele D'Alto  
Department of Cardiology  
Monaldi Hospital  
Naples  
Italy

Paola Argiento  
Department of Cardiology  
Monaldi Hospital  
Naples  
Italy

Anna Correra  
Department of Cardiology  
Monaldi Hospital  
Naples  
Italy

Giovanni Maria Di Marco  
Department of Cardiology  
Monaldi Hospital  
Naples  
Italy

Chiara Cresci  
Pneumology Unit  
Careggi University Hospital  
Florence  
Italy

Vieri Vannucchi  
Pneumology Unit  
Careggi University Hospital  
Florence

Italy

Elena Torricelli  
Pneumology Unit  
Careggi University Hospital  
Florence  
Italy

Alessio Garcea  
Pneumology Unit  
Careggi University Hospital  
Florence  
Italy

Alberto Pesci  
Pneumology Clinic  
Cardiothoracic and Vascular Department  
San Gerardo Hospital  
Monza  
Italy

Luca Sardella  
Pneumology Clinic  
Cardiothoracic and Vascular Department  
San Gerardo Hospital  
Monza  
Italy

Giuseppe Paciocco  
Pneumology Clinic  
Cardiothoracic and Vascular Department  
San Gerardo Hospital  
Monza  
Italy

Federico Pane  
Pneumology Clinic  
Cardiothoracic and Vascular Department  
San Gerardo Hospital  
Monza  
Italy

Andrea Maria D'Armini  
Cardiothoracic and Vascular Department  
Policlinico San Matteo  
Pavia  
Italy

Maurizio Pin  
Cardiothoracic and Vascular Department  
Policlinico San Matteo



Pavia  
Italy

Valentina Grazioli  
Cardiothoracic and Vascular Department  
Policlinico San Matteo  
Pavia  
Italy

Giulia Massola  
Cardiothoracic and Vascular Department  
Policlinico San Matteo  
Pavia  
Italy

Antonio Sciortino  
Cardiothoracic and Vascular Department  
Policlinico San Matteo  
Pavia  
Italy

Renato Prediletto  
Institute of Clinical Physiology  
Toscana Gabriele Monasterio Foundation  
CNR Research Area  
Pisa  
Italy

Carolina Bauleo  
Institute of Clinical Physiology  
Toscana Gabriele Monasterio Foundation  
CNR Research Area  
Pisa  
Italy

Edoardo Airò  
Institute of Clinical Physiology  
Toscana Gabriele Monasterio Foundation  
CNR Research Area  
Pisa  
Italy

Rudina Ndreu  
Institute of Clinical Physiology  
Toscana Gabriele Monasterio Foundation  
CNR Research Area  
Pisa  
Italy

Ivana Pavlickova

Institute of Clinical Physiology  
Toscana Gabriele Monasterio Foundation  
CNR Research Area  
Pisa  
Italy

Claudio Lunardi  
Department of Medicine  
Integrated University Hospital Verona  
Verona  
Italy

Massimiliano Mulè  
Department of Cardiology  
Policlinico Vittorio Emanuele  
Catania  
Italy

Silvia Farruggio  
Department of Cardiology  
Policlinico Vittorio Emanuele  
Catania  
Italy

Serena Costa  
Department of Cardiology  
Policlinico Vittorio Emanuele  
Catania  
Italy

Giuseppe Galgano  
Division of Cardiology  
Miulli General Hospital  
Fonti-Bari  
Italy

Mario Petruzzi  
Division of Cardiology  
Miulli General Hospital  
Fonti-Bari  
Italy

Anna De Luca  
Division of Cardiology  
Miulli General Hospital  
Fonti-Bari  
Italy

Francesco Lombardi  
Division of Cardiology  
Miulli General Hospital

Fonti-Bari  
Italy

Loris Roncon  
Department of Cardiology  
Hospital Santa Maria della Misericordia  
Rovigo  
Italy

Luca Conte  
Department of Cardiology  
Hospital Santa Maria della Misericordia  
Rovigo  
Italy

Claudio Picariello  
Department of Cardiology  
Hospital Santa Maria della Misericordia  
Rovigo  
Italy

Gil Wirtz  
Pneumology Service  
Centre Hospitalier de Luxembourg  
Luxembourg

Myriam Alexandre  
Pneumology Service  
Centre Hospitalier de Luxembourg  
Luxembourg

A. Vonk-Noordegraaf  
VU Medisch Centrum  
Amsterdam  
The Netherlands

H. Boogaard  
VU Medisch Centrum  
Amsterdam  
The Netherlands

J. Mager  
Department of Pulmonology  
St Antonius Ziekenhuis  
Nieuwegein  
The Netherlands

H. Reesink  
Department of Pulmonology  
St Antonius Ziekenhuis  
Nieuwegein

The Netherlands

Leon M. van den Toorn  
Department of Pulmonary Diseases  
Erasmus Medical Centre  
Rotterdam  
The Netherlands

Karin Boomars  
Department of Pulmonary Diseases  
Erasmus Medical Centre  
Rotterdam  
The Netherlands

Arne K. Andreassen  
Department of Cardiology  
Oslo University Hospital Rikshospitalet  
Oslo  
Norway

Graça Castro  
Department of Cardiology  
Coimbra Hospital and University Center  
Coimbra  
Portugal

Gonçalves Tania  
Department of Cardiology  
Coimbra Hospital and University Center  
Coimbra  
Portugal

Rui Baptista  
Department of Cardiology  
Coimbra Hospital and University Center  
Coimbra  
Portugal

António Marinho  
Department of Cardiology  
Coimbra Hospital and University Center  
Coimbra  
Portugal

Teresa Shiang  
Department of Pneumology  
Hospital Center Vila Nova de Gaia/Espinho  
Vila Nova de Gaia  
Portugal

Ana Oliveira

Department of Pneumology  
Hospital Center Vila Nova de Gaia/Espinho  
Vila Nova de Gaia  
Portugal

Daniel Coutinho  
Department of Pneumology  
Hospital Center Vila Nova de Gaia/Espinho  
Vila Nova de Gaia  
Portugal

Joana Sousa  
Department of Pneumology  
Hospital Center Vila Nova de Gaia/Espinho  
Vila Nova de Gaia  
Portugal

Maria José Loureiro  
Cardiology Department  
Hospital Garcia de Orta, E.P.E.  
Almada  
Portugal

Débora Repolho  
Cardiology Department  
Hospital Garcia de Orta, E.P.E.  
Almada  
Portugal

Susana Maria Martins Jesus  
Department of Medicine I  
North Lisbon Hospital Center  
Lisbon  
Portugal

Marta Capinha  
Department of Medicine I  
North Lisbon Hospital Center  
Lisbon  
Portugal

João Agostinho  
Department of Medicine I  
North Lisbon Hospital Center  
Lisbon  
Portugal

Tania Cardoso  
Department of Medicine I  
North Lisbon Hospital Center  
Lisbon

Portugal

Andreia Rocha  
Department of Medicine I  
North Lisbon Hospital Center  
Lisbon  
Portugal

Mafalda Espinha  
Department of Medicine I  
North Lisbon Hospital Center  
Lisbon  
Portugal

Kyundyul Ivanovich Ivanov  
State Budgetary Institution of the Republic of Sakha (Yakutia) "Republican Hospital №1 - National Center for Medicine"  
Yakutsk  
Russia

Dalyana Eduardovna Alexeeva  
State Budgetary Institution of the Republic of Sakha (Yakutia) "Republican Hospital №1 - National Center for Medicine"  
Yakutsk  
Russia

Marina Vadimovna Batalina  
State Educational Institution of Higher Professional Education "Orenburg State Medical University"  
Orenburg  
Russia

Daria Viktorovna Hegya  
State Budgetary Healthcare Institution "Primorskaya Regional Clinical Hospital №1"  
Vladivostok  
Russia

Tatyana Nikolaevna Zvereva  
Federal State Budgetary Scientific Institution "Research Institute for Complex Problems of Cardiovascular Diseases"  
Kemerovo  
Russia

Sergey Nikolaevich Avdeev  
Federal State Budgetary Institution "Scientific Research Institute of Pulmonology of the Federal Bio-Medical Agency"  
Moscow  
Russia

Natalia Anatolievna Tsareva  
Federal State Budgetary Institution "Scientific Research Institute of Pulmonology of the Federal Bio-Medical Agency"

Moscow  
Russia

Albert Sarvatovich Galyavich  
State Budgetary Institution of High Professional Education "Kazan State Medical University"  
Kazan  
Russia

Bykov Aleksander Nikolaevich  
State Budgetary Healthcare Institution "Sverdlovsk Regional Clinical Hospital No.1"  
Yekaterinburg  
Russia

Evgeny Vladimirovich Filippov  
State Budget Institution of the Ryazan region "Regional Clinical Cardiology Dispensary"  
Ryazan  
Russia

Olga Eduardovna Yakovleva  
Chelyabinsk Regional Cardiology Clinic  
Chelyabinsk  
Russia

Olga Borisovna Pavlova  
Perm Regional State Budgetary Healthcare Institution "Clinical Cardiology Dispensary"  
Perm  
Russia

Elena Sergeevna Skripkina  
State Autonomous Healthcare Institution Amur Region "Amur Regional Clinical Hospital"  
Blagoveschensk  
Russia

Tamila Vitalievna Martynyuk  
Federal State Budget Institution "Russian Cardiology Research and Production Complex" of the  
Russian Federation  
Moscow  
Russia

Irina Fedorovna Bukatova  
Regional State Budgetary Healthcare Institution "Regional Clinical Hospital №1"  
Khabarovsk  
Russia

Anna Viktorovna Tregubova  
State Budgetary Healthcare Institution "Volgograd Regional Clinical Cardiology Center"  
Volgograd  
Russia

Dmitry Yurievich Platonov

State Budgetary Healthcare Institution "Regional Clinical Hospital"  
Tver  
Russia

Tatyana Mikhaylovna Kolomeytseva  
State Healthcare Institution "City Hospital No.13 in Tula"  
Tula  
Russia

Abdullah Al Dalaan  
Pulmonary Medicine Section  
Department of Medicine  
King Faisal Specialist Hospital and Research Center  
Riyadh  
Saudi Arabia

Abeer Abeer Abdelsayed  
Pulmonary Medicine Section  
Department of Medicine  
King Faisal Specialist Hospital and Research Center  
Riyadh  
Saudi Arabia

Ihab Weheba  
Pulmonary Medicine Section  
Department of Medicine  
King Faisal Specialist Hospital and Research Center  
Riyadh  
Saudi Arabia

Sarferaz Saleemi  
Pulmonary Medicine Section  
Department of Medicine  
King Faisal Specialist Hospital and Research Center  
Riyadh  
Saudi Arabia

Hussam Sakkijha  
Pulmonary Medicine  
King Fahad Medical City  
Riyadh  
Saudi Arabia

Marcela Bohacekova  
Department of Cardiology and Angiology  
Faculty of Medicine  
Slovak Medical University & National Institute of Cardiovascular Diseases  
Bratislava  
Slovak Republic



Tatiana Valkovicova  
Department of Cardiology and Angiology  
Faculty of Medicine  
Slovak Medical University & National Institute of Cardiovascular Diseases  
Bratislava  
Slovak Republic

Iveta Farkasova  
Department of Cardiology and Angiology  
Faculty of Medicine  
Slovak Medical University & National Institute of Cardiovascular Diseases  
Bratislava  
Slovak Republic

Carlos Andres Quezada  
Department of Cardiology  
Hospital 12 de Octubre  
Madrid  
Spain

Lucilla Piccari  
Hospital Clínic-IDIBAPS  
University of Barcelona  
Barcelona  
Spain

Isabel Blanco  
Hospital Clínic-IDIBAPS  
University of Barcelona  
Barcelona  
Spain

Laura Sebastian  
Hospital Clínic-IDIBAPS  
University of Barcelona  
Barcelona  
Spain

Antonio Roman  
Department of Medicine  
Hospital Vall Hebron  
Barcelona  
Spain

Manuel Lopez  
Department of Medicine  
Hospital Vall Hebron  
Barcelona  
Spain

Remedios Otero

Medical-Surgical Unit of Respiratory Diseases  
University Hospital Virgen Del Rocio  
Seville  
Spain

Teresa Elias  
Medical-Surgical Unit of Respiratory Diseases  
University Hospital Virgen Del Rocio  
Seville  
Spain

Luis Jara  
Medical-Surgical Unit of Respiratory Diseases  
University Hospital Virgen Del Rocio  
Seville  
Spain

Isabel Asencio  
Medical-Surgical Unit of Respiratory Diseases  
University Hospital Virgen Del Rocio  
Seville  
Spain

Josefa Jiménez Arjona  
Department of Internal Medicine  
Hospital De Jerez  
Jerez De La Frontera  
Spain

Raúl Menor Almagro  
Department of Internal Medicine  
Hospital De Jerez  
Jerez De La Frontera  
Spain

Salvador López Cárdenas  
Department of Internal Medicine  
Hospital De Jerez  
Jerez De La Frontera  
Spain

Salvador Alcaraz García  
Department of Internal Medicine  
Hospital De Jerez  
Jerez De La Frontera  
Spain

Patricia Villanueva Rodríguez  
Department of Internal Medicine  
Hospital De Jerez  
Jerez De La Frontera

Spain

Raquel Lopez  
Pneumology Department  
Hospital La Fe  
Valencia  
Spain

Alberto Garcia  
Pneumology Department  
Hospital La Fe  
Valencia  
Spain

Francisco Fernandez Avilés  
Department of Cardiology  
Hospital Gregorio Marañón  
Madrid  
Spain

Sebastian De La Pava  
Department of Cardiology  
Hospital Gregorio Marañón  
Madrid  
Spain

Raquel Yotti  
Department of Cardiology  
Hospital Gregorio Marañón  
Madrid  
Spain

Gregorio Pérez Peñate  
Pneumology Service  
Hospital Dr Negrin  
Las Palmas  
Spain

Fernando León Marrero  
Pneumology Service  
Hospital Dr Negrin  
Las Palmas  
Spain

José Manuel Cifrián Martínez  
Servicio de Anestesiología y Reanimación  
Hospital Marques de Valdecilla  
Santander  
Spain

Amaya Martinez-Meñaca

Servicio de Anestesiología y Reanimación  
Hospital Marques de Valdecilla  
Santander  
Spain

Lecue Pilar Alonso  
Servicio de Anestesiología y Reanimación  
Hospital Marques de Valdecilla  
Santander  
Spain

Sonia Fernandez Rozas  
Servicio de Anestesiología y Reanimación  
Hospital Marques de Valdecilla  
Santander  
Spain

David Iturbe Fernandez  
Servicio de Anestesiología y Reanimación  
Hospital Marques de Valdecilla  
Santander  
Spain

Victor Mora Cuesta  
Servicio de Anestesiología y Reanimación  
Hospital Marques de Valdecilla  
Santander  
Spain

Stefan Söderberg  
Heart Center  
Norrland University Hospital  
Umeå  
Sweden

Sven-Erik Bartfay  
Department of Cardiology  
Sahlgrenska University Hospital  
Göteborg  
Sweden

Bengt Rundqvist  
Department of Cardiology  
Sahlgrenska University Hospital  
Göteborg  
Sweden

Monthir Alfetlawi  
Department of Cardiology  
Linköping University Hospital

Linköping  
Sweden

Peter Wodlin  
Department of Cardiology  
Linköping University Hospital  
Linköping  
Sweden

Esther Irene Schwarz  
Clinic of Pulmonology  
University Hospital Zurich  
Zurich  
Switzerland

Rudolf Speich  
Clinic of Pulmonology  
University Hospital Zurich  
Zurich  
Switzerland

Frédéric Lador  
Pulmonary Division  
Geneva University Hospitals  
Geneva  
Switzerland

Thierry Rochat  
Pulmonary Division  
Geneva University Hospitals  
Geneva  
Switzerland

Paola Gasche-Soccal  
Pulmonary Division  
Geneva University Hospitals  
Geneva  
Switzerland

Chih-Hsin Hsu  
Department of Internal Medicine  
National Cheng Kung University Hospital  
Tainan City  
Taiwan

Tsung-Hsien Lin  
Department of Medicine  
Kaohsiung Medical University Hospital  
Kaohsiung  
Taiwan

Ho-Ming Su  
Department of Medicine  
Kaohsiung Medical University Hospital  
Kaohsiung  
Taiwan

Wen-Ter Lai  
Department of Medicine  
Kaohsiung Medical University Hospital  
Kaohsiung  
Taiwan

Chun Yuan Chu  
Department of Medicine  
Kaohsiung Medical University Hospital  
Kaohsiung  
Taiwan

Po-Chao Hsu  
Department of Medicine  
Kaohsiung Medical University Hospital  
Kaohsiung  
Taiwan

Wen-Chol Voon  
Department of Medicine  
Kaohsiung Medical University Hospital  
Kaohsiung  
Taiwan

Hsueh-Wei Yen  
Department of Medicine  
Kaohsiung Medical University Hospital  
Kaohsiung  
Taiwan

Jacob Yih-Jer Wu  
Cardiovascular Center  
Mackay Memorial Hospital  
Taipei City  
Taiwan

Shu-Hao Wu  
Cardiovascular Center  
Mackay Memorial Hospital  
Taipei City  
Taiwan

Wen-Pin Huang  
Division of Cardiology  
Heart Center

Cheng Hsin General Hospital  
Taipei City  
Taiwan

Man-Cai Fong  
Division of Cardiology  
Heart Center  
Cheng Hsin General Hospital  
Taipei City  
Taiwan

Chien-Lung Huang  
Division of Cardiology  
Heart Center  
Cheng Hsin General Hospital  
Taipei City  
Taiwan

Ping-Hung Kuo  
Department of Internal Medicine  
National Taiwan University Hospital  
Taipei City  
Taiwan

Yen-Hung Lin  
Department of Internal Medicine  
National Taiwan University Hospital  
Taipei City  
Taiwan

Jiunn-Lee Lin  
Department of Internal Medicine  
National Taiwan University Hospital  
Taipei City  
Taiwan

Chi-Sheng Hung  
Department of Internal Medicine  
National Taiwan University Hospital  
Taipei City  
Taiwan

Cho-Kai Wu  
Department of Internal Medicine  
National Taiwan University Hospital  
Taipei City  
Taiwan

Shih-Hsien Sung  
Department of Medicine

Taipei Veterans General Hospital  
Taipei City  
Taiwan

Wei-Chun Huang  
Department of Cardiology  
Kaohsiung Veterans General Hospital  
Kaohsiung City  
Taiwan

Chin-Chang Cheng  
Department of Cardiology  
Kaohsiung Veterans General Hospital  
Kaohsiung City  
Taiwan

Shu-Hung Kuo  
Department of Cardiology  
Kaohsiung Veterans General Hospital  
Kaohsiung City  
Taiwan

Wen-Hwa Wang  
Department of Cardiology  
Kaohsiung Veterans General Hospital  
Kaohsiung City  
Taiwan

Wan-Jing Ho  
Department of Internal Medicine  
Chang Gung Memorial Hospital, Linkou  
Taoyuan County  
Taiwan

Tsu-Shiu Hsu  
Department of Internal Medicine  
Chang Gung Memorial Hospital, Linkou  
Taoyuan County  
Taiwan

Bülent Mutlu  
Department of Cardiology  
Marmara University Faculty of Medicine  
Istanbul  
Turkey

Halil Atas  
Department of Cardiology  
Marmara University Faculty of Medicine  
Istanbul



Turkey

Gul Ongen  
Department of Chest Diseases  
Istanbul University Cerrahpasa Faculty of Medicine  
Istanbul  
Turkey

Zeynep Un  
Department of Chest Diseases  
Istanbul University Cerrahpasa Faculty of Medicine  
Istanbul  
Turkey

Gulfer Okumus  
Istanbul Faculty of Medicine  
Istanbul University  
Istanbul  
Turkey

Zeynep Un  
Istanbul Faculty of Medicine  
Istanbul University  
Istanbul  
Turkey

Ismail Hanta  
Department of Respiratory Medicine  
Cukurova University  
Adana  
Turkey

Paul Corris  
Department of Respiratory Medicine  
Freeman Hospital  
Newcastle  
United Kingdom

Andrew Peacock  
Scottish Pulmonary Vascular Unit  
Golden Jubilee National Hospital  
Clydebank  
West Dunbartonshire  
United Kingdom

Colin Church  
Scottish Pulmonary Vascular Unit  
Golden Jubilee National Hospital  
Clydebank  
West Dunbartonshire  
United Kingdom

Mark Toshner  
Pulmonary Vascular Disease Unit  
Royal Papworth Hospital  
Cambridge  
United Kingdom

Michael Newnham  
Pulmonary Vascular Disease Unit  
Royal Papworth Hospital  
Cambridge  
United Kingdom

**Declaration of interests**

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☒ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Prof Marius M. Hoepfer reports honoraria for lectures and/or consulting from Acceleron, Actelion, Bayer AG, Gilead Sciences, Inc., Janssen-Cilag, MSD, and Pfizer. Dr Hans Klose reports speaker and consultancy fees from Actelion, Bayer AG, GSK, Novartis, Pfizer, and United Therapeutics and research support from Actelion, Bayer AG, GSK, Pfizer, and MSD. Dr Michael Halank reports personal fees and non-financial support from Actelion, AstraZeneca, Bayer AG, Berlin-Chemie, GSK, OMT, MSD, and Novartis. Dr George Giannakoulas reports speaker and consultancy fees from Actelion, Bayer, ELPEN Pharmaceuticals, GSK, Pfizer, Lilly and United Therapeutics, and research support from GSK, ELPEN Pharmaceuticals, and Galenica. Dr Henning Gall has received honoraria and/or other support from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics. Dr Pavel Jansa reports consultancy and speaker fees from MSD, AOP Orphan, and Actelion. Prof Ekkehard Grünig reports Research grants and speaker honoraria / consultancy fees from Actelion and Bayer/MSD, research grants from GSK, United Therapeutics, Bellerophon, OMT GmbH, Pfizer, Reata, and Novartis, and speaker honoraria from Bial, Medscape, and Orpha Swiss GmbH. Prof David Pittrow reports personal fees from Actelion, Bayer, Aspen, Boehringer Ingelheim, Sanofi, Biogen, Shire, and MSD outside the submitted work. Silvia Ulrich reports research grants and personal fees from Actelion, Bayer, MSD and Orpha Swiss. Tobias J. Lange has received personal fees from Actelion, MSD, Pfizer, and OMT orphan. Dr Iraklis Tsangaris reports speaker and consultancy fees from Actelion, Bayer AG, ELPEN, GSK, MSD, Pfizer, and United Therapeutics. Stephan Rosenkranz reports remunerations for lectures and/or consultancy from Abbott, Actelion, Arena, Bayer, Ferrer, GSK, MSD, Novartis, Pfizer, and United Therapeutics; and research support to his institution from Actelion, Bayer, Novartis, Pfizer, and United Therapeutics. R.J. Snijder reports grants from Pfizer and Actelion Pharmaceuticals. Prof. Iveta Šimková reports consultancy and speaker fees from MSD, AOP Orphan, and Actelion. Dr. Marc Humbert reports grants and personal fees from Bayer and GSK, and personal fees from Actelion, Merck, and United Therapeutics. Marion Delcroix has received investigator, speaker, consultant, and steering committee member fees from Actelion, Bayer AG, Bellerophon, Eli Lilly, GlaxoSmithKline, MSD, Pfizer, Reata and Research grants from Actelion. Joan A. Barberá reports receipt of honoraria for consultation or speaker fees from Actelion and Merck; and research support through his institution from Actelion, Merck, GlaxoSmithKline and Ferrer. Joanna Pepke-Zaba reports research grants and speaker honoraria / consultancy fees from Actelion and Bayer/MSD, and GSK. Jean-Luc Vachiéry reports ongoing consultancies to Actelion, Sonnovie, Arena Pharma, Bial Portela, and Respira Therapeutics, past consultancies to AstraZeneca, BayerShering, CardioMEMS, Glaxo SmithKline, Pfizer, Merck, and United Therapeutics, and current membership of an advisory board or similar group for Actelion and Glaxo SmithKline. Jean-Luc Vachiéry's institution receives funding from Actelion Pharmaceuticals for performing clinical studies. Regina Steringer-Mascherbauer, Jens Klotsche, and Miguel-Angel Gomez Sanchez have no conflicts of interest relevant to the EXPERT study. Hossein-Ardeschir Ghofrani reports personal fees for advisory board work, and payment for lectures including service on speaker bureaus, from Actelion, Bayer, GSK, Novartis, and Pfizer; consultancy fees from Actelion, Bayer, Bellerophon Pulse Technologies, GSK, MSD, Novartis, and Pfizer; and grants from Deutsche Forschungsgemeinschaft (DFG). Pilar Escibano-Subias reports personal fees from Actelion, Bayer AG, GlaxoSmithKline, and Merck Sharp & Dohme, and grants from Actelion, Bayer AG, GlaxoSmithKline, and Ferrer, outside the submitted work. Gérald Simonneau reports grants, personal fees, and non-financial support from Actelion Pharmaceuticals, Bayer AG, Merck, and GSK. Douglas S. Helmersen reports industry-sponsored research with Bayer AG, United Therapeutics, and Gilead Sciences, Inc., and advisory board/speaker fees from Bayer AG and Actelion. David Langleben reports honoraria, consultation fees, research support, and/or travel expenses from Actelion, Arena, Bayer AG, Northern Therapeutics, PhaseBio and United Therapeutics. Anco Boonstra reports consultancy fees from Pfizer BV and hospitality from Teva Nederland. Lisa M. Mielniczuk reports speaker fees and honoraria from Bayer AG, and speaker fees, consultancy fees, and travel fees from Actelion. Evgenia Williams and Christian Meier are employees